4.7 Letter

Improved survival of men 50 to 75 years old with acute myeloid leukemia over a 20-year period

Journal

BLOOD
Volume 134, Issue 18, Pages 1558-1561

Publisher

AMER SOC HEMATOLOGY
DOI: 10.1182/blood.2019001728

Keywords

-

Categories

Funding

  1. Swedish Cancer Society
  2. Swedish Association of Local Authorities and Regions
  3. Region Skane
  4. Regionalt Cancercentrum Syd

Ask authors/readers for more resources

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Letter Hematology

Decreasing early mortality in acute myeloid leukaemia in Sweden 1997-2014: improving performance status is a major contributing factor

Asa Derolf, Gunnar Juliusson, Lina Benson, Yngvar Floisand, Vladimir Lazarevic, Petar Antunovic, Lars Mollgard, Soren Lehmann, Bertil Uggla, Anders Wahlin, Martin Hoglund, Stefan Deneberg

BRITISH JOURNAL OF HAEMATOLOGY (2020)

Letter Hematology

Real-world data on treatment patterns and outcomes of hypomethylating therapy in patients with newly diagnosed acute myeloid leukaemia aged ≥ 60 years

Albin Osterroos, Anna Eriksson, Petar Antunovic, Jorg Cammenga, Stefan Deneberg, Vladimir Lazarevic, Fryderyk Lorenz, Lars Mollgard, Asa R. Derolf, Bertil Uggla, Lovisa Wennstrom, Emma Olander, Martin Hoglund, Gunnar Juliusson, Soren Lehmann

BRITISH JOURNAL OF HAEMATOLOGY (2020)

Editorial Material Hematology

Why classical cytogenetics still matters in acute myeloid leukemia

Vladimir Lj Lazarevic, Bertil Johansson

EXPERT REVIEW OF HEMATOLOGY (2020)

Article Multidisciplinary Sciences

Clonal competition within complex evolutionary hierarchies shapes AML over time

Carl Sanden, Henrik Lilljebjorn, Christina Orsmark Pietras, Rasmus Henningsson, Karim H. Saba, Niklas Landberg, Hanna Thorsson, Sofia von Palffy, Pablo Pena-Martinez, Carl Hogberg, Marianne Rissler, David Gisselsson, Vladimir Lazarevic, Gunnar Juliusson, Helena Agerstam, Thoas Fioretos

NATURE COMMUNICATIONS (2020)

Article Oncology

Subclonal patterns in follow-up of acute myeloid leukemia combining whole exome sequencing and ultrasensitive IBSAFE digital droplet analysis

Louise Pettersson, Yilun Chen, Anthony M. George, Robert Rigo, Vladimir Lazarevic, Gunnar Juliusson, Lao H. Saal, Mats Ehinger

LEUKEMIA & LYMPHOMA (2020)

Letter Hematology

Parental origin of monosomy 7 in acute leukaemia

Kristina B. Lundin-Strom, Andrea Biloglav, Vladimir Lazarevic, Mikael Behrendtz, Anders Castor, Bertil Johansson

BRITISH JOURNAL OF HAEMATOLOGY (2021)

Article Oncology

Is there an impact of measurable residual disease as assessed by multiparameter flow cytometry on survival of AML patients treated in clinical practice? A population-based study

Aldana Rosso, Gunnar Juliusson, Fryderyk Lorenz, Soren Lehmann, Asa Derolf, Stefan Deneberg, Martin Jadersten, Petar Antunovic, Jorg Cammenga, Lars Mollgard, Lovisa Wennstrom, Emma Olander, Mats Ehinger, Linda Fogelstrand, Martin Hoglund, Vladimir Lj Lazarevic

Summary: The Swedish national guidelines for AML treatment recommend analyzing MRD using MFC in the clinical setting. Most AML patients in complete remission after intensive chemotherapy had MRD-negative results, but there was no clear association with overall survival. Clinician awareness of the importance of MRD status could improve treatment outcomes.

LEUKEMIA & LYMPHOMA (2021)

Article Oncology

Mutational spectrum of de novo NPM1-mutated acute myeloid leukemia patients older than 75 years

Louise Pettersson, Benjamin Holmgren, Gunnar Juliusson, Vladimir Lj Lazarevic, Mats Ehinger

Summary: The mutational pattern of NPM1-mutated de novo AML may differ in very old patients compared to younger ones, with a significant enrichment of TET2 and SRSF2 mutations and a reduced frequency of DNMT3A mutations observed in the former group.

LEUKEMIA & LYMPHOMA (2021)

Letter Hematology

Impact of treatment delay in acute myeloid leukemia revisited

Gunnar Juliusson, Oskar Hagberg, Vladimir Lj Lazarevic, Soren Lehmann, Martin Hoglund

BLOOD ADVANCES (2021)

Review Medicine, General & Internal

Acute myeloid leukaemia in patients we judge as being older and/or unfit

V. Lj. Lazarevic

Summary: The definition of older age in AML is arbitrary, with various age thresholds used in clinical studies. Treatment decisions for older AML patients should be personalized and shared through dialogue with patients and their families. Despite advances in research and therapy, curing older patients with AML remains a challenge.

JOURNAL OF INTERNAL MEDICINE (2021)

Letter Oncology

Single base substitution and insertion/deletion mutational signatures in adult core binding factor acute myeloid leukemia

Rebeqa Gunnarsson, Minjun Yang, Andrea Biloglav, Vladimir Lazarevic, Kajsa Paulsson, Bertil Johansson

LEUKEMIA (2022)

Article Hematology

The prognostic impact of FLT3-ITD and NPM1 mutation in adult AML is age-dependent in the population-based setting

Gunnar Juliusson, Martin Jadersten, Stefan Deneberg, Soren Lehmann, Lars Mollgard, Lovisa Wennstrom, Petar Antunovic, Jorg Cammenga, Fryderyk Lorenz, Emma Olander, Vladimir Lj Lazarevic, Martin Hoglund

BLOOD ADVANCES (2020)

No Data Available